Home > Insider Trading > Filing (0001415889-23-004315)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1650664	Editas Medicine Inc.	EDIT	Biological Products, (No Disgnostic Substances) (2836)	464097528

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1755098	Michelle Robertson	C/O Editas Medicine, Inc. 11 Hurley St. Cambridge MA 02141	Evp, Chief Financial Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-03-02	31,500	$0.00	107,743	No	4	A	Direct
Common Stock	Disposition	2023-03-03	184	$8.89	107,559	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2023-03-02	94,500	$0.00	94,500	$8.72

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
94,500		2033-03-01	No	4	A	Direct

Footnotes

The common stock received by the Reporting person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2027.
Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on December 30, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2023. The sale does not represent a discretionary trade by the Reporting Person.
This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027.